Posts Tagged ‘retatrutide’

The slate is clean. All is forgiven. We have a fresh new year ahead. So that has us thinking about the trends that are likely to define 2026 in obesity, nutrition, and health. Here are five that floated to the top of our mind. 1. Healthy Weight for Life We have said it before. Weight […]

“I am over the moon about this,” said Harvard professor Caroline Apovian to us. She was talking about the outstanding topline results with retatrutide reported by Lilly from a phase three study. This is the so-called triple-G agonist that first stunned the world with its phase two results two years ago. In the results yesterday, […]

This is a perilous and exciting time for investing in obesity innovation as the market for treating this disease advances dramatically. On the side of excitement, we note that the David Wainer in the Wall Street Journal predicts that “obesity drugs are about to go mass market.” Perilous for Novo On the side of peril, […]

Retatrutide is that impressively potent obesity medicine that teased us with remarkable weight loss outcomes back in 2023. As we wait for pivotal phase three data (now due later this year), we wonder about the risk for muscle loss with a drug that has the potency of retatrutide. A new paper in Lancet Diabetes & […]

Novo Nordisk went shopping this week and brought home a super-early-phase triple-G agonist for the low low price of $200 million in cash up front. On top of that, Novo will pay another $1.8 billion plus royalties if all goes well. That’s a tidy sum to pay for rights to a drug – UBT251 – […]

Intriguing observations on the effect of retatrutide on cancer progression in mice appeared Friday in NPJ Metabolic Health and Disease. Retatrutide is the first triple agonist to progress in clinical development for obesity. Lilly said recently that they expect to release phase three clinical trial data for it later this year – earlier than previously […]

A concern is surfacing as obesity treatments become more and more effective. The measurement for success has long been percent weight loss. But thoughtful people have always known that the right target for obesity care was actually improved health. It was okay to focus on weight as a measure of effectiveness when the the effect […]

It’s enough to make our heads spin. The incredible vibrancy in obesity research is on full display at the meeting of the European Association for the Study of Diabetes – EASD 2023 in Hamburg. Today, it starts with a bang. Successive presentations on multi-agonists for obesity are scheduled this afternoon at EASD. But the abstracts […]

The last of four big days at ADA2023 brought us astonishing results from three studies of a new obesity medicine, retatrutide. This is the first 3-in-1 metabolic receptor agonist to advance this far in clinical trials as a medicine for obesity or diabetes. Researchers presented phase 2 results for obesity, diabetes, and NAFLD – three […]